Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.49 USD
+0.01 (0.68%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.47 -0.02 (-1.34%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
PTN 1.49 +0.01(0.68%)
Will PTN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PTN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PTN
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
PTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Other News for PTN
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
PharmaCorp Completes Acquisition of a Pharmacy in Western Canada
Patronus Resources Completes PNX Metals Acquisition
Buy Rating Affirmed for Palatin Technologies Amidst Promising Drug Developments and Clear FDA Pathways
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)